IP Verse

Laboratorios Liconsa, S.a. competitive analysis

Latest oppositions filed by Laboratorios Liconsa, S.a.

Explore patent oppositions filed by Laboratorios Liconsa, S.a. against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 10, 2026
Patent NumberTitleApplicantOpposition Date
EP3453387
Dosage Regimen For A S1P Receptor AgonistNOVARTISMar 3, 2021
EP3102187
Stable Pharmaceutical Compositions Containing Sitagliptin In The Form Of Immediate Release TabletsGALENICUM HEALTH SLDec 23, 2020
EP3103448
Pharmaceutical Compositions Comprising An S1P ModulatorNOVARTISApr 3, 2020
EP1785422
Micronised Crystalline Tiotropium BromideBOEHRINGER INGELHEIM PHARMA GMBH & CO. KGAug 16, 2017
EP2801355
Controlled Release Pharmaceutical Compositions Comprising A Fumaric Acid EsterFORWARD PHARMAJun 19, 2015
EP1880744
Bisphosphonic Acids For The Treatment And Prevention Of OsteoporosisATNAHS PHARMA UKFeb 12, 2015

Latest PTAB cases involving Laboratorios Liconsa, S.a.

Discover the latest PTAB cases involving Laboratorios Liconsa, S.a., highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Laboratorios Liconsa, S.a. with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 10, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
LABORATORIOS LICONSA, S.A.6 - - -
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG227 - -
F HOFFMANN LA ROCHE34231 - -
NOVARTIS12542 - 21